A novel interleukin 13 (IL-13) antagonist that blocks the biological activity of human IL-13 in immune and nonimmune cells.
Oshima
Y
Y
Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA.
Puri
R K
RK
D001667:Binding, Competitive; D004305:Dose-Response Relationship, Drug; D015536:Down-Regulation; D006801:Humans; D018793:Interleukin-13 / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors* / Q000494:pharmacology*; D053661:Interleukin-13 Receptor alpha1 Subunit; D018950:Lipopolysaccharide Receptors / Q000096:biosynthesis; D008954:Models, Biological; D009000:Monocytes; D018123:Receptors, Interleukin; D053660:Receptors, Interleukin-13; D015398:Signal Transduction / Q000187:drug effects
C508181:IL13RA1 protein, human; D018793:Interleukin-13; D053661:Interleukin-13 Receptor alpha1 Subunit; D018950:Lipopolysaccharide Receptors; D018123:Receptors, Interleukin; D053660:Receptors, Interleukin-13; C429824:interleukin-13 DM